ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information

Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: Canada
  • APO-Domperidone;
  • BIO-Domperidone;
  • Domperidone-10;
  • GMD-Domperidone;
  • JAMP-Domperidone;
  • Mar-Domperidone;
  • PMS-Domperidone [DSC];
  • Priva-Domperidone [DSC];
  • PRZ-Domperidone;
  • TARO-Domperidone;
  • TEVA-Domperidone
Pharmacologic Category
  • Dopamine Antagonist;
  • Gastrointestinal Agent, Prokinetic
Dosing: Adult

Note: Use the lowest effective dose for the shortest duration necessary.

GI motility disorders

GI motility disorders (diabetic gastroparesis, gastritis): Oral: 10 mg 3 times daily (maximum: 30 mg/day). The American College of Gastroenterology recommends initiating at 10 mg 3 times daily (Ref).

Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents

Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents: Oral: 10 mg 3 times daily (maximum: 30 mg/day).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Oral:

eGFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary (Ref).

eGFR <30 mL/minute/1.73 m2: 10 mg once or twice daily (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzed (large Vd): Oral: 10 mg once or twice daily (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (large Vd): Oral: 10 mg once or twice daily (Ref).

CRRT: Oral: Has not been studied; consider 10 mg once or twice daily (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: Has not been studied; consider administering 10 mg once or twice daily (Ref).

Dosing: Hepatic Impairment: Adult

Mild impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (undergoes hepatic metabolism).

Moderate or severe impairment: Use is contraindicated.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions (Significant): Considerations
Altered cardiac conduction

Domperidone may cause dose-related QT prolongation and sudden cardiac death observed initially with intravenous doses but also reported with oral administration (Ref).

Mechanism: Dose-related, related to pharmacologic action. Sudden cardiac death (SCD) results from the evolution of fatal arrhythmias, such as serious ventricular arrythmia (SVA). Drug-induced closure of the human ether a-go-go related gene (HERG) potassium efflux channel on the myocardium leads to the inhibition of the channel and thus the inability to move potassium out of the cell. This delays cardiac repolarization, which prolongs the QT interval and potentially leads to fatal arrythmia (eg, torsades de pointes) (Ref).

Onset: Varied; SVA/SCD and QTc prolongation are reported sporadically. Data are based on animal studies, case-control or cohort analysis, and exact exposure prior to the event is often unknown (Ref). Some data show the highest frequency of SCD with current domperidone use for 8 to 14 days (Ref). Consistent with this observation, a single retrospective analysis indicated the highest frequency of SVA/SCD events occurred after the initial domperidone prescription was dispensed, and the event frequency decreased with subsequent prescription refills (Ref).

Risk factors:

• Higher doses (>30 mg/day) (Ref)

• Concurrent use of drugs that are known to cause QT prolongation (Ref)

• Concurrent use of drugs that can increase serum concentrations of domperidone (Ref)

• Preexisting or familial history of QT prolongation (Ref)

• Electrolyte abnormalities (eg, hypokalemia, hyperkalemia, hypocalcemia, hypomagnesemia, hypoglycemia in the absence of diabetes) (Ref)

• Hepatic dysfunction (Ref)

• Older age (≥60 years) (Ref)

• History of cardiovascular disease (Ref)

• History of diabetes (Ref)

• Bradycardia (Ref)

• Status post-syncope or seizures, within the past 24 hours (Ref)

• History of chronic kidney failure requiring dialysis (Ref)

• Males (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Pruritus (≤1%), skin rash (≤1%), urticaria (≤1%)

Endocrine & metabolic: Galactorrhea not associated with childbirth (≤1%), gynecomastia (≤1%), hot flash (≤1%), increased thirst (≤5%), menstrual disease (≤1%)

Gastrointestinal: Abdominal pain (≤2%), acid regurgitation (≤2%), change in appetite (≤2%), constipation (≤2%), diarrhea (≤2%), dyspepsia (≤2%), nausea (≤2%), stomatitis (≤1%), xerostomia (≤5%)

Genitourinary: Mastalgia (≤1%)

Nervous system: Dizziness (≤5%), headache (≤5%), insomnia (≤5%), irritability (≤5%), lethargy (≤5%), migraine (≤5%), nervousness (≤5%)

Ophthalmic: Conjunctivitis (≤1%)

<1%:

Cardiovascular: Edema, palpitations

Endocrine & metabolic: Increased serum cholesterol, increased serum prolactin

Genitourinary: Dysuria, pollakiuria

Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase

Nervous system: Asthenia, extrapyramidal reaction

Neuromuscular & skeletal: Muscle spasm

Postmarketing:

Cardiovascular: Prolonged QT interval on ECG (Morris 2016), severe ventricular arrhythmia, torsades de pointes (Giudicessi 2018)

Endocrine & metabolic: Amenorrhea

Genitourinary: Erectile dysfunction

Neuromuscular & skeletal: Dystonia (Dhakal 2014), lupus-like syndrome (Yasue 1986)

Contraindications

Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals, particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg, heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg, ketoconazole), macrolides (eg, erythromycin), protease inhibitors, or nefazodone; concomitant use with QT-prolonging drugs

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Altered cardiac conduction: [Canadian Boxed Warning]: Domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses >30 mg or when used in patients >60 years of age. Use the lowest possible dose for the shortest duration necessary.

• Elevated prolactin levels: May increase prolactin levels (dose-dependent response); may be asymptomatic (clinical consequence of chronically elevated prolactin is unknown) or may present symptomatically as galactorrhea, gynecomastia, amenorrhea, or impotence (reversible upon decreasing dose or discontinuing drug). Use is contraindicated in patients with prolactinomas.

Disease-related concerns:

• Breast cancer: Use caution when administering to patients with a personal or family history of breast cancer; evidence regarding an association between chronic use of dopamine-receptor antagonists and breast cancer is limited and nonconclusive.

• Hepatic impairment: Undergoes extensive hepatic metabolism; use is contraindicated in patients with moderate to severe hepatic impairment; use with caution in mild impairment.

• Renal impairment: Use with caution in patients with severe renal impairment; dosage and/or frequency of administration may need adjusted with repeated use and/or long-term therapy. Monitor renal function regularly, particularly with long-term therapy.

Other warnings/precautions:

• Breast milk production stimulant: In 2004, the Food and Drug Administration (FDA) issued a warning recommending that domperidone not be used off-label to increase milk production in breast-feeding women due to safety concerns. Several cases of cardiac arrhythmia, cardiac arrest, and sudden death have been reported in patients receiving intravenous domperidone. The risk of similar adverse events in breast-feeding women is unknown. Domperidone is not available for any use in the United States (except via severe GI disorder IND) and does not have approval for this indication in other countries.

Product Availability

Not available in the US

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 10 mg

Prescribing and Access Restrictions

Domperidone is available via an Investigational New Drug Application (IND) in the United States for severe GI disorders refractory to standard therapy. For more information on the requirements for the IND, contact the Food and Drug Administration (FDA) at 301-796-3400.

Administration: Adult

Oral: In GI motility disorders, administer 15 to 30 minutes prior to meals and at bedtime if needed.

Use: Labeled Indications

Note: Not approved in the United States.

GI motility disorders: Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis

Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents: Prevention of GI symptoms (eg, nausea, vomiting) associated with use of dopamine-agonist anti-Parkinson agents

Medication Safety Issues
Sound-alike/look-alike issues:

Domperidone may be confused with iloperidone, paliperidone

Other safety concerns:

ALERT: Canadian Boxed Warning: Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Agents with Clinically Relevant Anticholinergic Effects: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Bromocriptine: Domperidone may diminish the therapeutic effect of Bromocriptine. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Domperidone. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Domperidone. Risk X: Avoid combination

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Domperidone. Risk X: Avoid combination

Fosfomycin: Gastrointestinal Agents (Prokinetic) may decrease the serum concentration of Fosfomycin. Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider therapy modification

Haloperidol: May enhance the QTc-prolonging effect of Domperidone. Risk X: Avoid combination

Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated. Risk X: Avoid combination

Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. Risk X: Avoid combination

Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. Risk C: Monitor therapy

Ondansetron: Domperidone may enhance the QTc-prolonging effect of Ondansetron. Risk X: Avoid combination

Opioid Agonists: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Pentamidine (Systemic): Domperidone may enhance the QTc-prolonging effect of Pentamidine (Systemic). Risk X: Avoid combination

Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities. Risk X: Avoid combination

QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Domperidone. Risk X: Avoid combination

QT-prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. Risk X: Avoid combination

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Domperidone may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. Risk X: Avoid combination

QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): Domperidone may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Domperidone. Risk X: Avoid combination

QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. Risk X: Avoid combination

Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Sirolimus (Conventional): Gastrointestinal Agents (Prokinetic) may increase the serum concentration of Sirolimus (Conventional). Risk C: Monitor therapy

Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. Risk X: Avoid combination

Food Interactions

Domperidone serum concentrations may be increased when taken with grapefruit juice. Management: Avoid concurrent use.

Pregnancy Considerations

Outcome data following maternal use of domperidone during pregnancy are limited. Based on available information from observational studies and health care database studies, an increased risk of adverse fetal events has not been observed following maternal use of domperidone in the first trimester (Araujo 2021; Choi 2013; Cottin 2015; Hishinuma 2021; Ishikawa 2022).

Breastfeeding Considerations

Domperidone is present in breast milk.

Data related to the presence of domperidone in breast milk are available from multiple studies (da Silva 2001; Hofmeyr 1983; Knoppert 2013; Krutsch 2023; Wan 2008).

• A study included 6 mothers of preterm infants (including two sets of twins and four singletons) with a postpartum milk production of <300 mL/day following 2 to 3 weeks of usual interventions to increase milk production. Domperidone was administered in doses of 30 or 60 mg/day in evenly divided doses every 8 hours and breast milk was sampled at intervals over 8 hours following 1 week of therapy. Median concentrations of domperidone in breast milk were 0.28 ng/mL following a 30 mg/day dose and 0.49 ng/mL with the 60 mg/day dose. Using the median milk concentrations, authors of the study calculated the estimated exposure to the breastfeeding infant to be 0.04 mcg/kg/day (relative infant dose 0.012% compared to a weight-adjusted maternal dose of 30 mg/day) or 0.07 mcg/kg/day (relative infant dose 0.009% compared to a weight-adjusted maternal dose of 60 mg/day) (Wan 2008).

• Domperidone was used in a study of women 14 to 21 days postpartum with a daily milk volume of <500 mL following delivery at <33 weeks' gestation. Patients in this study received oral domperidone 10 mg 3 times a day (n = 8) or 20 mg 3 times a day (n = 7) for 4 weeks. Breast milk was sampled 3, 6, and 8 hours after the maternal dose, between days 10 and 15 of therapy. The highest median milk concentration of domperidone was 6.9 ng/mL, which occurred 3 hours after the 20 mg dose. Mothers did not observe adverse events in the breastfed infants (Knoppert 2013). Using a milk concentration of 6.9 ng/mL, the relative infant dose of domperidone is 0.12% compared to a weight-adjusted maternal dose of 20 mg, providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day.

• Breast milk was evaluated in a patient taking domperidone 40 mg four times a day for 7 months. Four breast milk samples were provided over the course of 24 hours, ranging from 6.2 to 8.4 ng/mL. Using the average breast milk concentration (7 ng/mL) authors of the study calculated the relative infant dose of domperidone to be 0.05% compared to the weight-adjusted maternal dose (1.95 mg/kg/day), providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day (Krutsch 2023).

• One study reported events following maternal use of domperidone 10 mg 3 times daily (n = 45 mothers, 52 infants) or placebo (n = 45 mothers, 51 infants). Two cases of QTc interval change (442 to >500 msec) were noted in newborns in the domperidone group and 1 case in the placebo group after 14 days. There were no symptoms noted in the infants and no treatment was required (Asztalos 2017). Most available studies did not evaluate adverse events in breastfed infants following maternal use of domperidone (Shen 2021).

• Breastfeeding is not recommended by the manufacturer. However, breastfeeding is generally considered acceptable when the relative infant dose of a medication is <10% (Anderson 2016; Ito 2000).

Domperidone may increase prolactin concentrations and cause galactorrhea and gynecomastia. As such, it has been used off label as a galactagogue in patients with insufficient milk production. Pooled data from available studies note milk production may be increased over placebo (Foong 2020; Grzeskowiak 2018; Osadchy 2012; Paul 2015; Shen 2021; Taylor 2019).

Case reports describe the use of domperidone (in combination with other therapies) to induce lactation in non–gestational parents, including transgender patients undergoing feminizing hormone therapy, or adoptive patients who wish to breastfeed, and persons who wish to donate breast milk (Al-Mohsen 2021; Lopez-Bassols 2021; Reisman 2018; Schnell 2022; Wamboldt 2021).

Canadian product labeling notes domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses >30 mg or use in older patients. A retrospective study conducted by linking administrative health databases in Canada found the incidence of ventricular tachycardia or sudden cardiac death in postpartum patients between 15 and 55 years of age taking domperidone to be rare. Postpartum use of domperidone decreased over the study period (2004 to 2017) and any potential increased risk associated with these adverse events was not able to be confirmed. The data collected were not able to limit to only patients using domperidone for lactation but did exclude patients using domperidone prior to pregnancy (Moriello 2021). The risk of adverse cardiac events may be increased in patients with a history of arrythmias or those using concomitant medications that may inhibit the metabolism of domperidone (ABM [Brodribb 2018]).

Psychiatric symptoms, including insomnia, depression, and anxiety/panic attacks, have been reported in lactating patients upon tapering use of domperidone; suicidal and homicidal ideations have also been reported (Doyle 2018; Majdinasab 2022; Papastergiou 2013; Sharma 2022). Depression and thoughts of infanticide were reported in a patient after self-medicating with domperidone for 3 months to induce lactation after adopting a child. Symptoms improved following discontinuation of domperidone and 2 months of counseling and treatment with an antidepressant. This patient was also grieving the loss of another child. Authors of this case suggest domperidone should be used with caution in patients with previous psychiatric symptoms (Suain Bon 2022).

Domperidone is not approved for any indication in the United States. In addition, domperidone is not currently approved in any country as a galactagogue (Sewell 2017). The US Food and Drug Administration (FDA) has issued a warning recommending that domperidone not be used off label to increase milk production in breastfeeding patients due to safety concerns related to cardiac arrhythmias, cardiac arrest, and sudden death (FDA 2004). In Canada where domperidone is approved for other indications, a maximum daily dose has been recommended to decrease the incidence of abnormal heart rhythms and cardiac arrest (Health Canada 2015); some studies evaluating domperidone off label as a galactagogue have used doses higher than the maximum recommended labeled indication (Jantarasaengaram 2012; Knoppert 2013).

Due to the potential for adverse maternal events, a full evaluation for medical causes of low milk supply and nonpharmacologic measures should be considered prior to the use of medications as galactagogues. The Academy of Breastfeeding Medicine does not recommend use of any specific galactagogue due to inconclusive data and potential adverse effects. If use of domperidone is being considered, patients should be screened for a history of cardiac arrhythmias and concurrent use of medications that may increase the risk of arrhythmias. An ECG prior to use and 48 hours after domperidone is initiated may be considered for some patients. Various doses and durations of therapy have been suggested; generally, the maximum effect is observed by 7 to 14 days. The lowest possible dose for the shortest duration of time is recommended. In addition, consider a gradual discontinuation of domperidone (ABM [Brodribb 2018]).

Monitoring Parameters

Renal function; ECG (baseline and then periodically during therapy)

Mechanism of Action

Domperidone has peripheral dopamine receptor blocking properties and does not readily cross the blood-brain barrier. It increases esophageal peristalsis and increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time.

Pharmacokinetics (Adult Data Unless Noted)

Protein binding: 93%

Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation

Half-life elimination: 7 hours (increases to ~21 hours in severe renal impairment)

Time to peak serum concentration: 30 minutes

Excretion: Feces (66%); urine (31%)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Dompex | Dompy | Domstal | Mododom | Motilium | Motilone | Nausidom | Prokinin;
  • (AR) Argentina: Domperix | Ecuamon | Estocalm | Euciton | Gastrodom | Kinetidom | Moperidona | Motilium | Peridon | Voyou;
  • (AT) Austria: Motilium;
  • (AU) Australia: Apo Domperidone | Motilium;
  • (BD) Bangladesh: Adegut | Adorex | Anet | Apedom | Apidone | Apuldon | Atidon | Avomit | Benidon | Cosy | Dedom | Deflux | Degut | Domaid | Domar | Domfix | Domidon | Domilin | Domilux | Domin | Dominaaf | Dominat | Dominol | Domiren | Dompen | Dompi | Domsil | Domstol | Domtec | Don-a | Dopadon | Dopagut | Dopatic | Doperon | Dopon | Doridon | Dudon | Dysnov | Edone | Efodio | Egut | Emedon | Emidom | Eridon | Esogut | Evdom | Gidora | Gutset | Loval | Merin | Milium | Motigen | Motigut | Motil | Motilant | Motilex | Motinorm | Motiper | Motiwin | Myodon | Nudon | Omid | Omidon | P-Don | Paridon | Peridone-s | Perigut | Peristal | Predon | Prokinet | Protix | Ridon | Sagdon | Sb dom | Sydon | Tydon | Vave | Vegadon | Vomino | Xepadon | Xeridon;
  • (BE) Belgium: Docdomperi | Dompephar | Domperidone eurogenerics | Domperidone merck-generics | Domperidone teva generics belgium | Domperitop | Motilium | Noseum | Zilium;
  • (BF) Burkina Faso: Dulcan | Evidan | Gerdilium | Nauselium | Peridys;
  • (BG) Bulgaria: Costi | Motilium;
  • (BR) Brazil: Domped | Domperidona | Domperix | Domperol | Dompgran | Dompliv | Molidon | Motilium | Motiridona | Peridal | Peridona;
  • (CH) Switzerland: Motilium;
  • (CI) Côte d'Ivoire: Dulcan | Evidan | Gerdilium | Nauselium | Peridon;
  • (CL) Chile: Domperidona | Donegal | Dosin | Idon | Pipran | Restol | Siligaz;
  • (CN) China: Bao tai li tong | Domperid | Heng bang | Kuai ke lin | Li mei lin | Lu de lin | Ma ding lin | Motilium | Wei dong lin | You ma lin;
  • (CO) Colombia: Domperidona | Domperidona winthrop | Domperix | Harmetone | Isedron | Moperid | Norinpep;
  • (CZ) Czech Republic: Motilium;
  • (DE) Germany: Domidon | Domperidon | Domperidon 1 a pharma | Domperidon beta | Motilium;
  • (DO) Dominican Republic: Gastroflux | Motilium;
  • (EC) Ecuador: Dosin | Estocalm | Motilium;
  • (EE) Estonia: Motilium;
  • (EG) Egypt: Dompidone | Farcotilium | Gastromatil | Gastromotil | Motilium | Motinorm | Synchro-Git;
  • (ES) Spain: Domperidona gamir | Domperidona Pensa | Motilium | Nauzelin;
  • (ET) Ethiopia: Domperon;
  • (FR) France: Biperidys | Domperidone Actavis | Domperidone Almus | Domperidone Arrow | Domperidone arrow | Domperidone biogaran | Domperidone eg | Domperidone g gam | Domperidone gnr | Domperidone irex | Domperidone ivax | Domperidone merck | Domperidone Qualimed | Domperidone Ratiopharm | Domperidone rpg | Domperidone Sandoz | Domperidone Teva | Domperidone Zydus | Motilium | Peridys;
  • (GB) United Kingdom: Domilium | Domperidone | Domperidone Arrow | Domperidone kent | Domperidone Sandoz | Motilium | Vivadone;
  • (GR) Greece: Cilroton;
  • (HK) Hong Kong: Apo Domperidone | Apuldon | Costi | Dompedon | Dompeon | Domper m | Domperdone | Domperidon Stada | Doridone | Eurotilium | Floralin | Genolin | Kantuu | Monell | Motilium | Motione | Naupastad 10 | Neo ridone | Nidolium | Pesdon | Qualidom | Rabugen | Synotilium | Vemetis 10 | Vicktilin | Vicktilium;
  • (HU) Hungary: Motilium;
  • (ID) Indonesia: Costil | Digestadon | Dom | Dombaz | Dome | Domeran | Dometa | Dometic | Domperidon | Domperidone | Galdom | Galflux | Gerdilium | Grameta | Hufadon | Lexadon | Monell | Motilium | Myori | Nomesis | Novotil | Regit | Rosidon | Tilidon | Vesperum | Vidon | Vomecho | Vomerin | Vometa | Vomidone | Vomistop | Vomitas | Vosedon | Yaridon;
  • (IE) Ireland: Domerid | Motilium;
  • (IL) Israel: Motilium;
  • (IN) India: Acidopar | Aglodom | Aldom | Antem | Babydone | Cezvom | Denosia | Dimpy | Dom | Dom dt | Dom one | Dombax | Domcolic | Domel | Domeron | Domi | Domidone | Domitin | Domnat | Domolic | Dompar | Domped | Domper | Domperi | Domperistal | Dompon | Dompro | Dompy | Domsettler | Domstal | Domstal dt | Domtop | Domup | Domzen | Eldostal | Emidon | Emiges | Eminol | Emitex | Emitin | Emstal | Endopace | Enteridone | Gasidone | Gastractiv | Gastrium | Lupidom | Lydom | Montinorm | Motidom | Motilium m | Motinorm | Motiwin | Nausdan | Nausidome | Nautigo | Perid | Peridon | Prodom | Revert | Shidom | Stopvom | Toyodom | Unistal | Vindome | Vomidom | Vomilium | Vomirax | Vomistop | Zidon;
  • (IQ) Iraq: Domperid in | Domperisam | Motidon | Motiliufay;
  • (IT) Italy: Domperidone | Domperidone angenerico | Domperidone Ate | Domperidone copernico | Domperidone eg | Domperidone jet | Domperidone Merck Generics | Domperidone Ratio | Domperidone sandoz | Domperidone Tev | Mod | Motilium | Peridon | Permotil | Riges | Stalcare;
  • (JO) Jordan: Costi | Dompirid | Motilat | Motilium | Peridon | Prokinin;
  • (JP) Japan: Cobaperidon | Daiteredon | Dalic | Dalic Taiyo | Domperidone | Domperidone nichiiko | Domperidone sawai | Domperin | Drikker | Forimezin | Fuleiya | Hadodolin | Iridollin | Jackmar | Mionazelin | Monlobia | Nasirobin | Nausea | Nausiron | Nauzart | Nauzelin | Nyridone | Perizelin | Peroric | Selovase | Selovase chemiphar | Selovase teisan | Tohmine | Uperidone;
  • (KE) Kenya: Deflux | Domi | Domperon | Dompex | Domstal | Don a | Esogut | Lockit | Motil | Motilium | Motinorm | Peptomet | Prokinet | Ridon;
  • (KR) Korea, Republic of: Alvogen domperidone | Apepsia | Apepsia m | Borium | Borium m | Celltrion domperidone | Coperi | Darida | Dm | Domdon | Domdon m | Dompel | Dompel-m | Dompenyl | Domperidone | Domperidone bkw | Domperidone daewon | Domperiman | Domperin | Domperium m | Dompidone | Dompil | Domprin | Domtan tm | Donpedone | Donpel | Dopadon | Dopemine | Doprium | Emtridon | Feldon t | Gasco | Gasperin | Gasperin m | Gasperine | Gasteline | Gl domperidone | Hamidon | Hamidon m | Hanall domperidone maleate | Kanthidin | Maladon | Malidon | Maradon | Maradon-m | Maridone | Maridone-m | Monadon | Monadorine | Montes | Montes-m | Moparin m | Moperidone | Moperine m | Morem | Morinol | Morinol m | Morium | Motaridon | Motidin | Motildon | Motildon-m | Motilium | Motilium m | Motirem | Motirol | Muvidon | Muvidon m | Ompel | Peldon-t | Pelton | Peridium | Peridom | Perinal | Pesdon | Sama domperidone | Sanperidone | Shinperidone | Sinil domperidone | Soltina | Tameridone | Toriem | Trimodone | Unidon m | Unidone | Unidone m | Union domperidone | Wiroxin | Youngil domperidone maleate;
  • (KW) Kuwait: Domperidon hexal | Dompidone | Dompy | Gastromotil | Mododom | Motilium;
  • (LB) Lebanon: Domidone | Domperidone biogaran | Farcotilium | Mododom | Motilat | Motilium | Nauzex | Peridon | Pms Domperidone | Prokinin | Vomistop;
  • (LT) Lithuania: Domstal | Motilium;
  • (LU) Luxembourg: Motilium;
  • (LV) Latvia: Motilium;
  • (MA) Morocco: Biperidys | Motilium | Nauselium | Peridys | Prokinin;
  • (MX) Mexico: Biolix | Domperidona | Emefren | Motidom | Motilium | Seronex | Seronex lp;
  • (MY) Malaysia: Apo Domperidone | Dometic | Domil | Dompenyl | Domper | Hovid Smood | Molax-m | Moridone | Motidom | Motidone | Motigut | Motilidone | Motilium | Rabugen | Smood;
  • (NG) Nigeria: Motilium | Reamotil;
  • (NL) Netherlands: Domperidon | Domperidon accord | Domperidon Actavis | Domperidon eureco pharma | Domperidon flx | Domperidon hexal | Domperidon Mdq | Gastrocure | Motilium | San domperidon;
  • (NO) Norway: Cinet | Domperidon hexal | Domperidon Stada | Domperidon teva | Domperidone Winthrop | Motilium | Motilium janssen;
  • (NZ) New Zealand: Domperidone viatris | Motilium | Prokinex;
  • (PE) Peru: Domperidona | Donamin | Idon | Motilium | Netaf | Peridona;
  • (PH) Philippines: Abdopen | Accedome | Andiogan | Apuldon | Brudome | Degut | Domilium | Domne | Dompedone | Dompenyl | Domper | Domperidone Flamingo | Domperone | Domphil | Don-a | Dotilium | Dubamol | Flamilium | Gasidone | Gastrium | Gastromec | Gi norm | Gilax | Motilium | Motilux | Motinorm | Pepridon | Peridom | Perilax | Saphridone | Toridon | Vometa | Zydom;
  • (PK) Pakistan: Aksotin | Alilium | Almedon | Avomit | Convel v | Costi | Deflux | Do one | Dolium | Domact | Dome One | Dome one | Domel | Domflash | Domflash oro | Domilium | Domino | Domipar | Domlis | Domofit | Domotin | Domozat | Dompedone | Domptilium | Dompy | Dompyrax | Domridone | Domycare | Donits | Donium | Dopedom | Dypin v | Emet | Emidone | Emiset | Emitilium | Emolium | Entevigor | Erolium | Ferrostar | Gasidon | Gastrocure | Gastrocure V | Gastroke | Gutset | Haito | Kinetic | Maprid | Mendon | Milium | Milium v | Molium | Moperium | Moticol | Motidil | Motil | Motilium | Motilium-v | Motim | Motireg | Motiwin | Movedon-v | Mt done | Naudon | Nendone | Nomit | Noslex | Nv-nil | Olidon | Omperin | Optilium | Pelton | Pelton v | Pericid | Perid | Perid M | Peridone | Perilium | Perill | Perimo | Peristal | Plidome | Prokin | Protomic | Rapidone | Relperi | Remato | Residone | Ri One | Ridon | Seldom | Sevidon | Sevidon-v | Stomacol | Stomeze | Talsis | Tilium | Tilium v | Unidon | Unidon V | Veldom | Vometa | Vomilux | Vomistop | Vomitil | Wabdom | Zoramid;
  • (PL) Poland: Domperidon abz | Motilium;
  • (PT) Portugal: Cinet | Domperidona | Mogasinte | Motilium | Nordonil | Remotil;
  • (PY) Paraguay: Domper | Domperidona 10 mg dutriec | Domperidona 10 mg millet | Domperidona empa | Domperidona quimfa | Emetan | Gastren | Idon | Moperidona | Motilium | Nausefin;
  • (QA) Qatar: Domperide | Dompy | Farcotilium | Gastromotil | Mododom | Mododom OS | Motilat | Motilium | Motilone | Nauselium | Prokinin;
  • (RO) Romania: Domstal;
  • (RU) Russian Federation: Damelium | Domet | Domperidon | Domperidon hexal | Domperidone | Domperidone Teva | Domperidone xantis | Domstal | Draspazol | Motilak | Motilium | Motinorm | Motizhekt | Motogastric | Motonium | Passagix;
  • (SA) Saudi Arabia: Amistop | Mododom | Motilium | Motilone | Nausidom;
  • (SE) Sweden: Domperidon ebb;
  • (SG) Singapore: Dompel | Dompenyl | Domper | Doridone | Gastrium | Mirax | Motilium;
  • (SI) Slovenia: Motilium | Tametil;
  • (SK) Slovakia: Costi;
  • (TH) Thailand: Auto | Avomit-m | Costi | Dany | Dipace | Dolium | Dom M | Domerdon | Domidone | Domilium | Domilium-m | Dominox | Domon | Domp-m | Dompado | Dompar | Domper m | Domperdone | Domperium m | Domperkress | Domperone | Donox-m | Dopabloc | Doperan | Duodone | Dupegan | Emex | Fadone | Falium | Lima | M tolium | Malum | Meridone | Mirax | Mirax-m | Mocydone | Mocydone-m | Modilin | Modomed | Molax | Molax-m | Molidom | Molum | Moridon | Moridon-m | Moti-m | Moticon | Motidom | Motidom-m | Motidone | Motil | Motilin | Motilium | Motilium m | Motyle | Movelium | Movelium-m | Ninlium | P-tilium | Patilum | Peptomet | Peridium | Peridom-m | Peridone | Perista | Phartilium | Pondperdone | Pondperdone-m | Rabugen | Rabugen-m | Sinolium | Stillium | Teperium | Tolium | Vermadon | Vesperidone | Vomidone | Vomitil-m;
  • (TN) Tunisia: Biperidys | Domper | Dompyrex | Motilium | Peridys | Perilium | Piradium | Vomicalm;
  • (TR) Turkey: Motilium | Motis;
  • (TW) Taiwan: Costi | D.M.P | Daweison | Dercon | Dompe | Dompedon | Domper | Domperan | Domtodone | Domtoo | Dopine | Dosin | Dotidone | Duoridone | Emetrol | Foselin | Gain-Tonin | Genolin | Kantuu | Ledolium "c.l." | Lidonin | Menton | Mewellin | Modone | Molin | Motaline | Moten | Motilium | Motin | Moturin | Newedon | Nidolium | Pelidone | Peptomet | Peridon | Rotilium | Sutonin | Suweida | Weitul | Wempty | Wyeanin;
  • (UA) Ukraine: Domidon | Domperidon | Domperidone | Domrid | Domrid sr | Doprokin | Gastropom apo | Motilium | Motinol | Motinorm | Motoricum | Motorix | Peridon | Perilium;
  • (UG) Uganda: Domi | Motilium | Motinorm | Prokinet;
  • (UY) Uruguay: Domper | Domperidoll | Domperidona | Domperidona Pellier | Domplexal | Euciton | Motilium;
  • (VE) Venezuela, Bolivarian Republic of: Domperidona | Dompidom | Dompidon | Domstal | Dosprol | Gasperix | Moperid | Tilium | Tonum;
  • (VN) Viet Nam: Agimoti | Becadom | Domreme | Hadilium | Modom s | Moti boston | Motimilum | Pedomcad | Ragozax | Vacodomtium;
  • (ZA) South Africa: Bio domperidone | Motilium | Vomidon;
  • (ZM) Zambia: Domidone | Domstal | Lockit | Motinorm;
  • (ZW) Zimbabwe: Domstal | Motilium
  1. Al-Mohsen ZA, Frookh Jamal H. Induction of lactation after adoption in a muslim mother with history of breast cancer: a case study. J Hum Lact. 2021;37(1):194-199. doi:10.1177/0890334420976333 [PubMed 33275500]
  2. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  3. Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2015.
  4. Araujo M, Vabre C, Benevent J, et al. Risk of pregnancy termination and congenital anomalies after domperidone exposure: a study in the EFEMERIS database. Drug Saf. 2021;44(7):787-796. doi:10.1007/s40264-021-01077-9 [PubMed 33970448]
  5. Asztalos EV, Campbell-Yeo M, da Silva OP, Ito S, Kiss A, Knoppert D; EMPOWER Study Collaborative Group. Enhancing human milk production with domperidone in mothers of preterm infants. J Hum Lact. 2017;33(1):181-187. doi:10.1177/0890334416680176 [PubMed 28107101]
  6. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411-421. doi:10.1111/j.1365-2125.2011.04093.x [PubMed 21883386]
  7. Brodribb W. ABM Clinical protocol #9: use of galactogogues in initiating or augmenting maternal milk production, second revision 2018. Breastfeed Med. 2018;13(5):307-314. doi:10.1089/bfm.2018.29092.wjb [PubMed 29902083]
  8. Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015;128(1416):66-74. [PubMed 26117678]
  9. Camilleri M, Parkman HP, Shafi MA, et al. Clinical Guideline: Management of Gastroparesis. Am J Gastroenterol. 2013;108(1):18-37. doi:10.1038/ajg.2012.373 [PubMed 23147521]
  10. Chen HL, Hsiao FY. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24(8):841-848. doi:10.1002/pds.3814 [PubMed 26098410]
  11. Choi JS, Han JY, Ahn HK, et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. J Obstet Gynaecol. 2013;33(2):160-162. doi:10.3109/01443615.2012.734871 [PubMed 23445139]
  12. Cottin J, Beghim D, Jonville-Bera AP, et al. First trimester exposure to domperidone: a comparative prospective study of exposed infants (abstract). Reproductive Toxicology. 2015;57:217.
  13. Cowan A, Garg AX, McArthur E, Muanda Tsobo F, Weir MA. Cardiovascular safety of metoclopramide compared to domperidone: A population-based cohort study. J Can Assoc Gastroenterol. 2021;4(5):e110-e119. doi:10.1093/jcag/gwaa041 [PubMed 34617008]
  14. da Silva OP, Knoppert DC, Angelini MM, et al. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ. 2001;164(1):17-21. [PubMed 11202662]
  15. Dhakal OP, Dhakal M, Bhandari D. Domperidone-induced dystonia: a rare and troublesome complication. BMJ Case Rep. 2014;2014:bcr2013200282. doi:10.1136/bcr-2013-200282 [PubMed 24973343]
  16. Domperidone-10 (domperidone) [product monograph]. Laval, Québec: Pro Doc LTÉE; July 2023.
  17. Doyle M, Grossman M. Case report: domperidone use as a galactagogue resulting in withdrawal symptoms upon discontinuation. Arch Womens Ment Health. 2018;21(4):461-463. doi:10.1007/s00737-017-0796-8 [PubMed 29090362]
  18. Drolet B, Rousseau G, Daleau P, et al. Domperidone Should Not be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders. Circulation. 2000;102(16):1883-1885. doi:10.1161/01.cir.102.16.1883 [PubMed 11034933]
  19. Dumitrascu DL, Weinbeck M. Domperidone Versus Metoclopramide in the Treatment of Diabetic Gastroparesis. Am J Gastroenterol. 2000;95(1):316-317. doi:10.1111/j.1572-0241.2000.01721.x [PubMed 10638616]
  20. Ehrenpreis ED, Roginsky G, Alexoff A, Smith DG. Domperidone is commonly prescribed with QT-interacting drugs: Review of a community-based practice and a postmarketing adverse drug event reporting database. J Clin Gastroenterol. 2017;51(1):56-62. doi:10.1097/MCG.0000000000000543 [PubMed 27182647]
  21. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  22. Field J, Wasilewski M, Bhuta R, et al. Effect of chronic domperidone use on QT interval: A large single center study. J Clin Gastroenterol. 2019;53(9):648-652. doi:10.1097/MCG.0000000000001183 [PubMed 30720577]
  23. Foong SC, Tan ML, Foong WC, Marasco LA, Ho JJ, Ong JH. Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. Cochrane Database Syst Rev. 2020;5(5):CD011505. doi:10.1002/14651858.CD011505.pub2 [PubMed 32421208]
  24. Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. doi:10.1111/nmo.13302 [PubMed 29441683]
  25. Grzeskowiak LE, Smithers LG, Amir LH, Grivell RM. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: a systematic review and meta-analysis. BJOG. 2018;125(11):1371-1378. doi:10.1111/1471-0528.15177 [PubMed 29469929]
  26. Health Canada. Summary Safety Review. DOMPERIDONE. Serious abnormal heart rhythms and sudden death (cardiac arrest), January 27, 2015. https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php#
  27. Hishinuma K, Yamane R, Yokoo I, et al. Pregnancy outcome after first trimester exposure to domperidone - an observational cohort study. J Obstet Gynaecol Res. 2021;47(5):1704-1710. doi:10.1111/jog.14709 [PubMed 33631840]
  28. Hofmeyr GJ, van Iddekinge B. Domperidone and lactation. Lancet. 1983;1(8325):647. doi:10.1016/s0140-6736(83)91818-4 [PubMed 6131323]
  29. Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol. 2013;61(3):218-225. doi:10.1097/FJC.0b013e31827afd0d [PubMed 23188128]
  30. Ishikawa T, Obara T, Akazawa M, et al. Risk of major congenital malformations associated with first-trimester exposure to propulsives: a health administrative database study in Japan. Pharmacoepidemiol Drug Saf. 2022;31(2):196-205. doi:10.1002/pds.5370 [PubMed 34628689]
  31. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  32. Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet. 2012;116(3):240-243. doi:10.1016/j.ijgo.2011.10.019 [PubMed 22189066]
  33. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881-888. doi:10.1002/pds.2016 [PubMed 20652862]
  34. Knoppert DC, Page A, Warren J, et al. The effect of two different domperidone doses on maternal milk production. J Hum Lact. 2013;29(1):38-44. doi:10.1177/0890334412438961 [PubMed 22554679]
  35. Krutsch K, Datta P. The transfer of domperidone into human milk remains low at high doses. Breastfeed Med. 2023;18(7):555-556. doi:10.1089/bfm.2023.0108 [PubMed 37352416]
  36. Lopez-Bassols I, Duke LO, Subramaniam G. Three continents, two fathers, one donor: a non-puerperal relactation case study. J Hum Lact. 2021;37(4):697-702. doi:10.1177/0890334421999327 [PubMed 33887977]
  37. Majdinasab E, Haque S, Stark A, Krutsch K, Hale TW. Psychiatric manifestations of withdrawal following domperidone used as a galactagogue. Breastfeed Med. 2022;17(12):1018-1024. doi:10.1089/bfm.2022.0190 [PubMed 36367713]
  38. Moriello C, Paterson JM, Reynier P, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Off-label postpartum use of domperidone in Canada: a multidatabase cohort study. CMAJ Open. 2021;9(2):E500-E509. doi:10.9778/cmajo.20200084 [PubMed 33990364]
  39. Morris AD, Chen J, Lau E, Poh J. Domperidone-associated QT interval prolongation in non-oncologic pediatric patients: a review of the literature. Can J Hosp Pharm. 2016;69(3):224-230. doi:10.4212/cjhp.v69i3.1560 [PubMed 27403002]
  40. Motilium (domperidone) tablets [prescribing information]. Macquarie Park NSW, Australia: Janssen-Cilag Pty Ltd; July 30, 2021. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-01258-3&d=20230323172310101
  41. Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893. doi:10.1155/2012/642893 [PubMed 22461793]
  42. Ou LB, Moriello C, Douros A, Filion KB. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2021;87(10):3649-3658. doi:10.1111/bcp.14737 [PubMed 33439512]
  43. Papastergiou J, Abdallah M, Tran A, Folkins C. Domperidone withdrawal in a breastfeeding woman. Can Pharm J (Ott). 2013;146(4):210-212. doi:10.1177/1715163513492928 [PubMed 23940477]
  44. Paul C, Zénut M, Dorut A, et al. Use of domperidone as a galactagogue drug: a systematic review of the benefit-risk ratio. J Hum Lact. 2015;31(1):57-63. doi:10.1177/0890334414561265 [PubMed 25475074]
  45. PRZ-Domperidone (domperidone) [product monograph]. Surrey, British Columbia, Canada: Pharmaris Canada Inc; November 2021.
  46. Refer to manufacturer's labeling.
  47. Renoux C, Dell'Aniello S, Khairy P, et al; Canadian Network for Observational Drug Effect Studies (CNODES) investigators. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. Br J Clin Pharmacol. 2016;82(2):461-472. doi:10.1111/bcp.12964 [PubMed 27062307]
  48. Reisman T, Goldstein Z. Case report: induced lactation in a transgender woman. Transgend Health. 2018;3(1):24-26. doi:10.1089/trgh.2017.0044 [PubMed 29372185]
  49. Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257-262. doi:10.2174/157488610791698334 [PubMed 20394569]
  50. Schnell A. Successful co-lactation by a queer couple: a case study. J Hum Lact. 2022;38(4):644-650. doi:10.1177/08903344221108733 [PubMed 35795891]
  51. Sewell CA, Chang CY, Chehab MM, Nguyen CP. Domperidone for lactation: what health care providers need to know. Obstet Gynecol. 2017;129(6):1054-1058. doi:10.1097/AOG.0000000000002033 [PubMed 28486375]
  52. Sharma V, Sharma S, Doobay M. Domperidone withdrawal in a nursing female with pre-existing psychiatric illness: a case report. Curr Drug Saf. 2022;17(3):278-280. doi:10.2174/1574886316666211013120735 [PubMed 34645378]
  53. Shen Q, Khan KS, Du MC, Du WW, Ouyang YQ. Efficacy and safety of domperidone and metoclopramide in breastfeeding: a systematic review and meta-analysis. Breastfeed Med. 2021;16(7):516-529. doi:10.1089/bfm.2020.0360 [PubMed 33769844]
  54. Smolina K, Mintzes B, Hanley GE, Oberlander TF, Morgan SG. The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiol Drug Saf. 2016;25(10):1210-1214. doi:10.1002/pds.4035 [PubMed 27296864]
  55. Stoetzer C, Voelker M, Doll T, Heineke J, Wegner F, Leffler A. Cardiotoxic antiemetics metoclopramide and domperidone block cardiac voltage-gated Na+ channels. Anesth Analg. 2017;124(1):52-60. doi:10.1213/ANE.0000000000001673 [PubMed 27861438]
  56. Suain Bon R, Mahmud AA. Domperidone use as a galactagogue and infanticide ideation: a case report. Breastfeed Med. 2022;17(8):698-701. doi:10.1089/bfm.2022.0016 [PubMed 35793516]
  57. Taylor A, Logan G, Twells L, Newhook LA. Human milk expression after domperidone treatment in postpartum women: a systematic review and meta-analysis of randomized controlled trials. J Hum Lact. 2019;35(3):501-509. doi:10.1177/0890334418812069 [PubMed 30481478]
  58. US Food and Drug Administration (FDA). FDA Talk Paper: FDA warns against women using unapproved drug, domperidone, to increase milk production. Published June 7, 2004. Accessed October 28, 2021. https://www.fda.gov/drugs/information-drug-class/fda-talk-paper-fda-warns-against-women-using-unapproved-drug-domperidone-increase-milk-production.
  59. van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-14. doi:10.2165/11536840-000000000-00000 [PubMed 20925438]
  60. Wamboldt R, Shuster S, Sidhu BS. Lactation induction in a transgender woman wanting to breastfeed: case report. J Clin Endocrinol Metab. 2021;106(5):e2047-e2052. doi:10.1210/clinem/dgaa976 [PubMed 33513241]
  61. Wan EW, Davey K, Page-Sharp M, Hartmann PE, Simmer K, Ilett KF. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol. 2008;66(2):283-289. doi:10.1111/j.1365-2125.2008.03207.x [PubMed 18507654]
  62. Wilcock A, Charlesworth S, Twycross R, et al. Prescribing non-opioid drugs in end-stage kidney disease. J Pain Symptom Manage. 2017;54(5):776-787. doi:10.1016/j.jpainsymman.2017.08.014 [PubMed 28843456]
  63. Yasue T, Nitta Y. Domperidone-induced systemic lupus-like syndrome. J Dermatol. 1986;13(4):293-296. doi:10.1111/j.1346-8138.1986.tb02943.x [PubMed 3540058]
Topic 8777 Version 241.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟